Publications

AW Harris, A Douds, EV Meurisse, S Chambers, SR Gould.
High seroprevalence of Helicobacter pylori in residents of a hospital for people with severe learning difficulties.
Eur J Gastroenterol Hepatol 1995; 7: 21-23

AW Harris, PA Gummett, RPH Logan, HA Ashworth, JJ Misiewicz, JH Baron.
Eradication of Helicobacter pylori with lansoprazole and clarithromycin.
Aliment Pharmacol Ther 1995; 9: 201-204

AW Harris, MM Walker, A Smolka, JM Waller, JH Baron, JJ Misiewicz.
Prevalence of parietal cells in the duodenal bulb & relationship to H pylori infection
Journal of Clinical Pathology 1996; 49: 309-312

AW Harris, PA Gummett, JJ Misiewicz, JH Baron.
Eradication of Helicobacter pylori lowers acid output in patients with duodenal ulcer.
Gut 1996; 38: 663-667

AW Harris, MM Walker, JM Waller, JH Baron, JJ Misiewicz.
The relationship between duodenal gastric metaplasia, acid output and H pylori
Gut 1996; 39: 513-520

AW Harris, DI Pryce, SM Gabe, et al.
Lansoprazole, clarithromycin & metronidazole for one week cures H pylori infection.
Aliment Pharmacol Ther 1996; 10 (6):1005-1008

AW Harris, PA Gummett, P Phull, MR Jacyna, JJ Misiewicz, JH Baron.
Recurrence of duodenal ulcer after H pylori eradication is related to high acid output
Aliment Pharmacol Ther 1997; 11: 331-334.

JJ Misiewicz, AW Harris, KD Bardham, et al.
One week triple therapy for Helicobacter pylori: a multi-centre comparative study.
Gut 1997; 41: 735-739

AW Harris, JJ Misiewicz, KD Bardham et al.
Incidence of duodenal ulcer healing after one week of PPI triple therapy for eradication of Helicobacter pylori.
Aliment Pharmacol Ther 1998; 12 (8): 741-745

Moayyedi P, on behalf of the Dyspepsia Review Group (includes AW Harris).
Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia.
BMJ 2000; 321: 659-664.

Fox MR, Harris AW.
An assessment of open access referral for PEG in a district general hospital.
Eur J Gastroenterol Hepatol 2002; 14 (11): 1245-49

Moayyedi P, Soo S, Deeks J, Forman D, Harris AW, Innes M, Delaney B.
Systematic review: antacids H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia.
Aliment Pharmacol Ther 2003: 17: 1215-1227

Hayee BH, Harris AW
Methotrexate for Crohn’s disease: experience in a district general hospital
Eur J Gastroenterol Hepatol 2005; 17 (9): 893-898

KM Taylor, K Arajs, T Rouse, AW Harris
Prospective audit of colonoscopy quality in Kent and Medway, UK.
Endoscopy 2008; 40:1-4

Russo EA, Harris AW, Campbell S, et al.
Experience of maintenance infliximab therapy for refractory ulcerative colitis in England.
Aliment Pharmacol Ther 2009; 29: 308-314

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart AL, Hamlin J, Orchard J, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O’Connor M, Harris AW, O’Morain C, Ghosh S.
Survey regarding the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland
Eur J Gastro Hepatol 2010;22 (3):334-9

Loft DE, Harris AW, Barrison IG. Revalidation of Gastroenterologists, with or with out sedation!
Frontline Gastroenterology 2010 (in press)

Reviews, Leading Articles and Letters in Learned Journals

AW Harris, JJ Misiewicz.
Hitting H. pylori for four
Lancet 1995; 345: 806-807.

AW Harris
Helicobacter pylori testing at home
Eur J Gastroenterol Hepatol 1995; 7: 595-596

AW Harris, JJ Misiewicz
Treating Helicobacter pylori - the best is yet to come?
Gut 1996; 39 (6): 781-783

AW Harris
Helicobacter pylori and urea breath testing. Can the breath test result predict the outcome of treatment?
Italian Journal of Gastroenterology and Hepatology 1998;30: 151-2

AW Harris
Current regimens for treatment of Helicobacter pylori
In: Farthing MJG and Patchett SE, eds. British Medical Bulletin: Helicobacter infection
1998; 54 (1): 195-205

AW Harris
Understanding Inflammatory Bowel Disease.
In: CR-ROM “Inflammatory Bowel Diseases” Schreiber S et al. Walter de Gruyter GmbH, Berlin, 1998

AW Harris
Drugs, Diseases and Disorders: Pentasa in ulcerative colitis
NHS Doctor and Commissioning GP Summer 1998: 57-8

AW Harris
Inflammatory bowel disease: safety of current therapies
Hospital Update Supplement August 1998: 9-10

AW Harris
Treatment of H pylori
World Journal of Gastroenterology 2001; 7 (3): 303-307

Adam Harris, JJ Misiewicz
Management of Helicobacter pylori infection
British Medical Journal 2001; 323: 1047-50

BH Hayee, AW Harris
6-mercaptopurine and mesalasine for prevention of relapse after conservative surgery for Crohn’s disease.
Gastroenterology 2005; 128(1): 249

G Sisson, AW Harris
Certolizumab Pegol for treatment of Crohn’s disease.
Gastroenterology 2006; 130(1): 285-286

K Taylor, AW Harris
Ulcerative Colitis: an overview
Chemist and Druggist 5 May 2007: 34-38

AW Harris
Gastroenterology in 2050
Hospital Doctor June 2007

Books

AW Harris, JJ Misiewicz.
Clinician's Manual on Helicobacter pylori
Science Press Limited, London, 1995 (Second edition 1997).

AW Harris, JJ Misiewicz.
Helicobacter pylori
Blackwell Scientific Publications Limited, Oxford, 1996.

AW Harris, JJ Misiewicz
Lecture notes on Helicobacter pylori
Rapid Science Press Limited, London, 1996.

AW Harris
CD-ROM: Peptic ulcer disease
RSM Press, London, 1998

Eds: Baron JH, Logan R, Harris AW, Misiewicz JJ.
ABC of Upper Gastrointestinal Tract
BMJ, London, 2002 (ISBN 0-7279-1266-6)

AW Harris
Handbook of Gastrointestinal Emergencies
Science Press Limited, London 2002 (ISBN 1-85873-394-4)

AW Harris
Starting Out in Private Practice. In: British Society of Gastroenterology Handbook for Private Practice, London 2010 (in press)

Recent Abstracts at National or International Gastroenterology Meetings

Maiden LP, Lawson GJ, Harris AW.
Development of human anti-murine antibodies in patients following treatment with infliximab.
Gut 2003; 52 (Suppl 1): A62

Maiden LP, Harris AW.
Parenteral methotrexate in refractory Crohn’s disease: experience in a district general hospital.
Gut 2003; 53 (Suppl 1): A63

Hayee BH, Barnden M, Harris AW.
Waiting list validation for screening and surveillance colonoscopy.
Gut 2005; 54 (Suppl 11): A74.

Hayee BH, Basavarajaiah, Harris AW.
Guided primary care management of inflammatory bowel disease.
Gut 2005; 54 (Suppl 11): A107.

AW Harris, K Arajs, T Rouse.
Prospective audit of colonoscopy quality in Kent & Medway
Gut 2006;55 (Suppl 11): A8

G Sisson, AW Harris.
Is conscious sedation practiced safely in patients undergoing colonoscopy
Gut 2006; 55 (Suppl 11): A 94

S McLaughlin, AW Harris
Audit of 30 day mortality following PEG insertion in a District General Hospital compared with NCEPOD results.
Gut 2007; 56 (suppl 1):A95

T Demetriou, C Gawad, C Kok, AW Harris.
Two year prospective audit of use of liquid diets as “bridge” therapy for active Crohn’s disease.
Gut 2008;57 (Suppl 1): A18

KM Taylor, AW Harris.
Infliximab as a treatment for ulcerative colitis: 3 years experience in a district general hospital.
Gut 2008;57 (Suppl 1): A149

Taylor KM, Lawson G, Harris AW.
Cardiac troponins in patients treated with biological therapy for inflammatory bowel disease
Journal of Crohn’s & Colitis 2009; 3 (1): S59

Taylor KM, Sharma H, Nedjat-Shokouhi B, Bird GL, Harris AW.
Retrospective study of outcomes of patients with Crohn’s disease treated with early immunosuppression.
Journal of Crohn’s & Colitis 2009; 3 (1): S66

Taylor KM, Harris AW.
Parenteral methotrexate for Crohn’s disease: 9 years experience in a district general hospital.
Journal of Crohn’s & Colitis 2009; 3 (1): S85

Blaker PA, Nedjat-Shokouhi B, Thomas DM, Harris AW.
Myenteric plexitis does not predict endoscopic Crohn’s disease recurrence 12 months following ileo-colonic resection in district general hospital practice.
Gut 2009; 58 (Suppl 1): A98

Russo EA, Lindsay JJ, Campbell S, Hart LA, Hamlin PJ, Orchard TR, Arebi N, Nightingale J, Jacyna MR, O'Connor M, Harris AW, O'Morain CA, Ghosh S.
Experience on the use of adalimumab as maintenance therapy in Crohn’s disease .
Gut 2009; 58 (Suppl 1): A61